We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

268 hedge funds and large institutions have $5.5B invested in Array Biopharma Inc in 2019 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 101 increasing their positions, 75 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

338% more call options, than puts

Call options by funds: $89.5M | Put options by funds: $20.4M

114% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 29

83% more capital invested

Capital invested by funds: $3B → $5.5B (+$2.5B)

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

35% more repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 75

14% more funds holding

Funds holding: 236 → 268 (+32)

Holders
268
Holders Change
+32
Holders Change %
+13.56%
% of All Funds
5.8%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.28%
New
62
Increased
101
Reduced
75
Closed
29
Calls
$89.5M
Puts
$20.4M
Net Calls
+$69.1M
Net Calls Change
+$50.4M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$123M
2
PA
Perceptive Advisors
New York
+$88M
3
MWNA
Marshall Wace North America
New York
+$52.9M
4
ACA
Avoro Capital Advisors
New York
+$41.6M
5
1832 Asset Management
1832 Asset Management
Ontario, Canada
+$33.4M

Top Sellers

1
RG
Redmile Group
California
-$114M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$84M
3
Millennium Management
Millennium Management
New York
-$30.8M
4
PAMU
Pictet Asset Management (UK)
United Kingdom
-$30.7M
5
BI
BVF Inc
California
-$27.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
126
Hollencrest Capital Management
California
$2.09M – – –
FAM
127
Fred Alger Management
New York
$2.07M +$1.77M +85,000 New
SEI Investments
128
SEI Investments
Pennsylvania
$2.01M +$1.49M +71,387 +662%
D.E. Shaw & Co
129
D.E. Shaw & Co
New York
$1.98M +$1.35M +64,794 +390%
MAP
130
Moody Aldrich Partners
Massachusetts
$1.91M -$596K -28,627 -27%
BA
131
Boston Advisors
Massachusetts
$1.87M +$458K +21,995 +40%
EGM
132
Engineers Gate Manager
New York
$1.81M +$1.54M +74,100 New
IBT
133
International Biotechnology Trust
United Kingdom
$1.77M – – –
DekaBank Deutsche Girozentrale
134
DekaBank Deutsche Girozentrale
Germany
$1.73M -$929K -44,600 -29%
AI
135
Axiom Investors
Connecticut
$1.71M -$1.01M -48,665 -41%
SO
136
STRS Ohio
Ohio
$1.69M +$331K +15,900 +30%
GAM
137
Gotham Asset Management
New York
$1.67M +$957K +45,948 +203%
MLICM
138
Metropolitan Life Insurance Company (MetLife)
New York
$1.65M -$13.2K -634 -0.9%
WMSA
139
Weiss Multi-Strategy Advisers
New York
$1.58M -$104K -5,000 -7%
Envestnet Asset Management
140
Envestnet Asset Management
Illinois
$1.55M +$525K +25,239 +66%
Royal Bank of Canada
141
Royal Bank of Canada
Ontario, Canada
$1.51M +$613K +29,453 +90%
AR
142
Advisory Research
Illinois
$1.51M +$454K +21,829 +54%
MSL
143
Mackay Shields LLC
New York
$1.51M -$6.25K -300 -0.5%
PMFA
144
Plante Moran Financial Advisors
Michigan
$1.37M -$62.5K -3,000 -5%
FP
145
Foundry Partners
Minnesota
$1.37M +$1.17M +56,148 New
Stifel Financial
146
Stifel Financial
Missouri
$1.33M +$225K +10,810 +25%
TI
147
Trexquant Investment
Connecticut
$1.28M -$270K -12,970 -20%
GPCM
148
Granite Point Capital Management
Massachusetts
$1.22M +$1.04M +50,000 New
N
149
Nuveen
North Carolina
$1.22M +$1.04M +49,976 New
BNP Paribas Financial Markets
150
BNP Paribas Financial Markets
France
$1.2M +$669K +32,117 +190%
4 5
6
7 8

ARRY Hedge Fund Activity: Q1 2019 in Review

268 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2019, worth a combined $5.5B — up 83% from $3B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new ARRY positions and 29 closed out — a net gain of 33 holders — while 101 added to existing stakes and 75 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $123M. The largest seller was Redmile Group, cutting an estimated $114M.

  • 268 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2019, up from 236 in Q4 2018.
  • Funds reported $5.5B of Array Biopharma Inc stock for Q1 2019, up 83% quarter-over-quarter.
  • 62 funds opened new Array Biopharma Inc positions in Q1 2019 and 29 closed out, a net change of +33 holders.
  • The largest Array Biopharma Inc buyer in Q1 2019 was T. Rowe Price Associates, an estimated $123M added.
  • The largest Array Biopharma Inc seller in Q1 2019 was Redmile Group, an estimated $114M sold.

Based on aggregated 13F filings for Q1 2019.